BACKGROUND: Our objective was to describe the prevalence of the metabolic syndrome using World Health Organization (WHO) and National Cholesterol Education Program (NCEP-III) definitions in a population-based survey. METHODS: We performed an analysis of data from a Mexican nationwide, population-based study. The population was composed of 2,158 men and women aged 20-69 years sampled after a 9-12 h fasting period. Prevalence of the metabolic syndrome as defined by the NCEP-III definition and WHO criteria was estimated and case characteristics were assessed. RESULTS: Age-adjusted prevalence was 13.61% for WHO criteria and 26.6% for the NCEP-III definition. Prevalence was 9.2 and 21.4%, respectively, in subjects without diabetes. Thirty five percent of affected cases were <40 years of age. In addition to criteria used for diagnosis, ca. 90% were either overweight or obese. In cases detected using WHO criteria, antihypertensive treatment or blood pressure reading >140/90 was found in 61.8%. The proportion of subjects who qualified for hypolipemiant treatment was lower: lifestyle modifications were needed in 42.1% and drug therapy was required in 18.9%. The same trends were found for cases detected using the NCEP definition. CONCLUSIONS: Prevalence of the metabolic syndrome in Mexico is high. A large proportion of affected cases qualify for preventive actions for complications of the metabolic syndrome (i.e., weight loss, antihypertensive or hypolipemiant treatment). These results provide data for planning therapeutic programs for Mexican patients with the metabolic syndrome.
BACKGROUND: Our objective was to describe the prevalence of the metabolic syndrome using World Health Organization (WHO) and National Cholesterol Education Program (NCEP-III) definitions in a population-based survey. METHODS: We performed an analysis of data from a Mexican nationwide, population-based study. The population was composed of 2,158 men and women aged 20-69 years sampled after a 9-12 h fasting period. Prevalence of the metabolic syndrome as defined by the NCEP-III definition and WHO criteria was estimated and case characteristics were assessed. RESULTS: Age-adjusted prevalence was 13.61% for WHO criteria and 26.6% for the NCEP-III definition. Prevalence was 9.2 and 21.4%, respectively, in subjects without diabetes. Thirty five percent of affected cases were <40 years of age. In addition to criteria used for diagnosis, ca. 90% were either overweight or obese. In cases detected using WHO criteria, antihypertensive treatment or blood pressure reading >140/90 was found in 61.8%. The proportion of subjects who qualified for hypolipemiant treatment was lower: lifestyle modifications were needed in 42.1% and drug therapy was required in 18.9%. The same trends were found for cases detected using the NCEP definition. CONCLUSIONS: Prevalence of the metabolic syndrome in Mexico is high. A large proportion of affected cases qualify for preventive actions for complications of the metabolic syndrome (i.e., weight loss, antihypertensive or hypolipemiant treatment). These results provide data for planning therapeutic programs for Mexican patients with the metabolic syndrome.
Authors: Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel Journal: Endocr Rev Date: 2008-10-29 Impact factor: 19.871
Authors: Carmen M Gurrola-Díaz; Sergio Sánchez-Enriquez; Edith Oregon-Romero; Pedro M García-López; Pedro Garzón de la Mora; Blanca E Bastidas-Ramírez; Mercedes González-Hita; José F Muñoz-Valle Journal: J Clin Lab Anal Date: 2009 Impact factor: 2.352
Authors: Cihangir Erem; Arif Hacihasanoglu; Orhan Deger; Murat Topbaş; Ilgin Hosver; Halil Onder Ersoz; Gamze Can Journal: Endocrine Date: 2008-03-13 Impact factor: 3.633
Authors: Daphna Weissglas-Volkov; Carlos A Aguilar-Salinas; Elina Nikkola; Kerry A Deere; Ivette Cruz-Bautista; Olimpia Arellano-Campos; Linda Liliana Muñoz-Hernandez; Lizeth Gomez-Munguia; Maria Luisa Ordoñez-Sánchez; Prasad M V Linga Reddy; Aldons J Lusis; Niina Matikainen; Marja-Riitta Taskinen; Laura Riba; Rita M Cantor; Janet S Sinsheimer; Teresa Tusie-Luna; Päivi Pajukanta Journal: J Med Genet Date: 2013-03-15 Impact factor: 6.318
Authors: Felix I Tellez-Avila; Francisco Sanchez-Avila; Mauricio García-Saenz-de-Sicilia; Norberto C Chavez-Tapia; Ada M Franco-Guzman; Gustavo Lopez-Arce; Eduardo Cerda-Contreras; Misael Uribe Journal: World J Gastroenterol Date: 2008-08-14 Impact factor: 5.742
Authors: Daphna Weissglas-Volkov; Carlos A Aguilar-Salinas; Janet S Sinsheimer; Laura Riba; Adriana Huertas-Vazquez; Maria L Ordoñez-Sánchez; Rosario Rodriguez-Guillen; Rita M Cantor; Teresa Tusie-Luna; Päivi Pajukanta Journal: Circ Cardiovasc Genet Date: 2009-12-11
Authors: Jorge Escobedo; Herman Schargrodsky; Beatriz Champagne; Honorio Silva; Carlos P Boissonnet; Raul Vinueza; Marta Torres; Rafael Hernandez; Elinor Wilson Journal: Cardiovasc Diabetol Date: 2009-09-26 Impact factor: 9.951